Fascinating post, MD Virologist. Perhaps you will entertain

New Post Public Reply Private Reply Replies (1) Message Board
havasu78 MD VIROLOGIST #41382
1,092
Fascinating post, MD Virologist. Perhaps you will entertain a few questions on which I would say you are uniquely qualified to offer a perspective.

It appears to me that CCR5/CCL5/RANTES has emerged suddenly and unexpectedly as a critical pathway in many diseases.

Am I imagining that sudden emergence? As physician and/or scientist in this field, do you find the emergence of CCR5/CCL5/RANTES to be a relatively new, and somewhat sudden, research area?

The emergence of leronlimabCYDY for covid19 is so interesting for so many personal, scientific, economic, and business issues.

It almost seems as if Patterson's potentially watershed RANTES/covid19 publication is a key that will unlock development efforts in many different, and previously unrelated, diseases. All because of the previously unknown, or at least untargeted, CCR5/CCL5 immune function.

It is quite remarkable how the CCR5/CCL5 axis appears so powerful in so many disease conditions, and it seems equally remarkable that the CCR5/CCL5 axis has not been previously targeted in any of these diseases.

Blood CCL5 chemokine gradient propels immune cells to the locations of tumors and inflammation. In solid tumors, the CCR5/CCL5 axis and CCL5 chemokine gradient may play a key role in how the tumor microenvironment prevents infiltration of cancer killing immune cells. In covid19, the CCL5 chemokine gradient may be the primary factor that causes cytokine syndrome.

In other autoimmune diseases besides covid19 such as MS or alzheimers, the CCL5 chemokine gradient may be the cause of excessive immune cell infiltration and damage.

In metastatic solid tumors where the tumor cells overexpress CCR5, the CCR5 receptor activation seems to confer some sort of motility upon the cancer cell which causes the the cancer cell to leave the tumor, enter the bloodstream, and travel to some other tissue to cause a metastatic tumor.

No doubt the mechanism of action for some lernlimab results is still unknown. In Patterson's preprint, repolarization of macrophages is an important result. Patterson's covid19 macrophage result is entirely concordant with the covid19 results of lenzilumab and mavrilinumb, which are antibodies to granulocyte macrophage colony stimulating factor (GMCSF). Why is it that antibodies binding GMCSF in blood has the same effect as blocking activation of CCR5 on the macrophages?

For some CCR5 blocker immune applications, the reason for CCR5 involvement in inflammation may as yet be completely undiscovered. This might be the case for the leronlimab mouse studies in MS, which the researchers described as "never having seen results like that before".

For all of these diseases, it seems the state-of-the-art has suddenly stumbled upon the importance of CCR5/CCL5 in all of these diseases, and Cytodyn is the tip of the spear.

What I wonder is: Given the multiplicity of diseases that might be targeted with a CCR5 blocking molecule, how come there are no candidate molecules for the task? Seems to me its leronlimab and maraviroc. And both of those were developed for HIV.

clinicaltrials.gov reports 75,488 results for the search term "cancer".

Add CCL5, and there are 11 results. Add RANTES, and there are 9 results. Add CCR5, and there are 19 results.

So of 75,488 clinical cancer trials only 39 even measure CCR5/CCL5/RANTES, let alone posit them as primary factors. That's less than one out of one thousand human clinical trials.

MD Virologist, can you comment on what appears to me to be this situation where RANTES/CCL5/CCL4 has been totally overlooked as to its potential primary involvement in many diseases?

If it has been overlooked, what might be the reason for that?

And I wonder about the extent to which Patterson expected to find RANTES as the cause of covid19?

Do you think he anticipated that CCR5 receptor mediated chemotaxis might be the cause of covid19 cytokine response syndrome? Or was he just taking some wild guesses?

The emergence of leronlimab/CYDY for covid just seems so much like a bolt of lightning from a clear blue sky.

Why didn't anyone think of this before?

My favorite comment from Pourhassan is from the April 27 youtube:

...we were not on the map (for Covid19). Nobody thought we were on the map (for Covid19) and we didn't know either. Dr. Patterson and Dr. Scott Kelly had talked about it and then when Dr. Harish Seethamraju from Montefiore Medical Center heroically came and said "I need this" that started everything.

It seems like nobody had a clue that the CCL5 chemokine gradient was attracting the excessive immune response. And then suddenly the CCL5 chemokine gradient makes sense in so many other diseases.
1

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Chicken Production Rises Amid Meat Market Shifts

Updated Category News Views 41

Protein Markets Scramble: Chicken Production Climbs Here’s a tasty tidbit that might just have investors reeling: the USDA says chicken production will be cruising on the up, whereas beef is taking a bit of a backseat. Yep, the big birds are flying higher, and the cows, well, they're just mooing a little softer. And what's that mean for big players like Tyson...

Continue Reading
Baidu's Q3 2026: AI Explodes Amid Marketing Slump

Updated Category News Views 59

Baidu Looks to AI as Revenue Driver in Q3 2026 You know, Baidu's got one heck of a story this quarter. Despite some clouds hanging over them, they’ve managed to find a silver lining in their AI ventures. It’s like they’ve got this magic bullet with AI Cloud growth skyrocketing 94% year over year. That’s not just a rabbit outta the hat; it’s more like pulling a...

Continue Reading
Sandals Foundation: Win a Trip, Boost Caribbean Education

Updated Category News Views 68

Sandals Resorts Stakes a Claim in Education While the rest of us are gravitating towards Black Friday deals and Cyber Monday sales, the Sandals Foundation decided to play a different game. This Giving Tuesday, they invite travelers not just to soak in the sun, but to spread a little of it around by supporting education for kids across the Caribbean. It's a classic example...

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 114

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 114

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
A&G Management's Bold New Era with WPM Partnership

Updated Category News Views 122

Shaking Up Baltimore's Real Estate Scene Swapping up management partners can be a dicey game, but A&G Management seems to be pulling it off without a hitch. As of January 4, 2027, WPM Real Estate Management will take over the reins for more than 3,000 apartment homes scattered across Anne Arundel, Howard, and Baltimore counties. A new set of hands is stepping in for...

Continue Reading
Lecanemab Shines in 5-Year Alzheimer's Study at CTAD

Updated Category News Views 71

Latest Lecanemab Results Turn Heads at CTAD 2026 The whispers buzzing out of the CTAD 2026 conference are about something promising for those in the trenches of Alzheimer's research: lecanemab. Yep, it's a name that's been bandied about before, and this time it's the long-term data doing the talking. The five-year results from Eisai and Biogen's lecanemab study are...

Continue Reading
Pinot's Palette Expands with New La Quinta Studio

Updated Category News Views 57

Canvas and Cabernet in Coachella Valley Grab your brushes and wine glasses; Pinot's Palette is branching out to La Quinta. As of November 27, locals and visitors alike can find their artistic flair at 47120 Dune Palms Road. This move isn’t just another business expansion—it's about blending community spirit with creativity, backed by the experienced entrepreneurs...

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 247

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading
Charlotte's Top-Tier Home Sales Surge: A $15M Milestone

Updated Category News Views 95

Charlotte's Luxury Market: A Rapid Ascent Folks, buckle up, because the luxury home market in Charlotte isn't just on the rise—it's practically sky-high. Back in 2016, the idea of splashing out over $5 million on a house was almost unheard of in this neck of the woods. Only one brave soul did it at the time. Fast forward to this past year, and things are looking starkly...

Continue Reading

Top 5 Most Recently Viewed Articles

Sanoma Corporation's Recent Share Buyback Explained

Updated Category News Views 173

Insights into Sanoma Corporation's Share Buyback Activity Sanoma Corporation has conducted a significant share buyback, underscoring its commitment to enhancing shareholder value. These transactions were announced through a stock exchange release, giving investors an insightful look into the company's market activities. Details of the Buyback Transaction On a noteworthy...

Continue Reading
Finland's Real Estate Market Thrives in 2025: Key Insights

Updated Category News Views 248

The Resurgence of Finland's Real Estate Market Finland's real estate market is experiencing an inspiring recovery, marked by increasing transaction volumes and growing investment liquidity. This positive trend not only showcases renewed confidence among local investors but also reflects heightened interest from international players in the Finnish market. Analysts predict...

Continue Reading
Investors Alert: Join the Fight for Justice with aTyr Pharma

Updated Category News Views 190

Understanding the aTyr Pharma Situation Investors of aTyr Pharma Inc. are facing a challenging and distressing time following recent revelations regarding the company’s performance. The company is known for its innovative approaches in the realm of pharmaceuticals and has garnered significant attention in the stock market. However, the recent downturn in share value has...

Continue Reading
Fly Play hf. Reports Q2 Losses Amid External Challenges

Updated Category News Views 143

Profit Warning for Fly Play hf. Recently, Fly Play hf. shared concerns regarding its upcoming Q2 2025 interim financial report. The company anticipates that their results will fall short of last year’s performance and internal expectations. A net loss of around USD 16 million is projected for this quarter, compared to a loss of USD 10 million during the same period last...

Continue Reading
Olin Corporation Faces Challenges Amid Earnings Report

Updated Category News Views 85

Olin Corporation Reports Disappointing Third Quarter Earnings Olin Corporation (NYSE: OLN) recently announced its earnings for the third quarter of 2024, revealing significant challenges that led to a 14% drop in its stock price. This downturn was driven primarily by the fallout from Hurricane Beryl and a decline in demand within its ammunition division. Financial...

Continue Reading